Matej Mikulic
Research expert covering health, pharma & medtech
Merck & Co. - Statistics & Facts
Merck & Co. has solidified its position as one of the leading pharmaceutical companies worldwide, driven primarily by the exceptional performance of its blockbuster cancer drug Keytruda. In 2025, the company's total revenue reached 65 billion U.S. dollars, marking continued growth in a competitive global pharmaceutical market. This strong financial performance underscores the New Jersey-headquartered company's ability to deliver innovative treatments that address critical healthcare needs.
Oncology leadership anchored by Keytruda
The company's oncology portfolio remains its most significant revenue driver. Keytruda generated over 31 billion U.S. dollars in revenue during 2025, making it not only Merck's flagship product but also the best-selling pharmaceutical drug globally. The cancer immunotherapy drug with the generic name pembrolizumab has consistently expanded its reach, treating various forms of cancer and securing a dominant position in the oncology market. In early 2026, Merck created a standalone oncology division to better focus on launching new cancer treatments and preparing for Keytruda's 2028 patent expiration in the U.S. market.
Strong market position amid fierce competition
Within the highly competitive pharmaceutical landscape, Merck maintains a prominent position among industry leaders. As of early 2026, the company held a market capitalization of nearly 294 billion U.S. dollars, placing it among the top ten biotech and pharmaceutical companies globally. The company's prescription drug sales and substantial research and development investments demonstrate its commitment to maintaining long-term competitiveness and developing the next generation of breakthrough therapies.
Diversified portfolio and geographic reach
Beyond its oncology dominance, Merck maintains a diversified pharmaceutical portfolio spanning multiple therapeutic areas including vaccines, diabetes treatment, cardiovascular health, and animal health. The company's geographic footprint is equally broad, with approximately half of its total revenue generated from its domestic United States market in 2025, while maintaining substantial presence across Europe, the Middle East, Africa, and Asia-Pacific regions. This balanced approach helps mitigate regional market risks while capitalizing on growth opportunities in different healthcare markets worldwide.
